趋化因子受体CXCR3在套细胞淋巴瘤中的表达及临床意义  

Expression and Clinical Significance of CXCR3 in Mantle Cell Lymphoma

作　　者：朱明霞[1] 万文丽[1] 洪韫 朱晓雯 胡凯[1] 万伟[1] 景红梅[1] 克晓燕[1] ZHU Ming-Xia;WAN Wen-Li;HONG Yun;ZHU Xiao-Wen;HU Kai;WAN Wei;JNG Hong-Mei;KE Xiao-Yan(Department of Hematology,Beijing University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院血液科

出　　处：《中国实验血液学杂志》2019年第6期1831-1837,共7页Journal of Experimental Hematology

基　　金：国家自然科学基金项目(81700188)

摘　　要：目的:探讨趋化因子受体CXCR3在套细胞淋巴瘤(MCL)中的表达情况及其临床意义。方法:采用流式细胞术检测在北京大学第三医院血液科诊疗的25例初治MCL患者淋巴结和结外组织中趋化因子受体CXCR3表达情况,分析CXCR3的表达水平与患者重要临床特征以及预后因素的关系。结果:25例患者送检肿瘤标本均不同程度表达CXCR3,淋巴结和骨髓中肿瘤细胞CXCR3表达水平高于外周血,且骨髓中表达强度与受累细胞数量呈正相关。CXCR3high组患者外周血淋巴细胞绝对值和血红蛋白水平均显著低于CXCR3low组(P<0.05),肿瘤细胞CXCR3表达水平与血乳酸脱氢酶(LDH)水平、β2-微球蛋白(β2-MG)水平、Ki-67指数、MIPI评分以及骨髓累及程度呈显著相关(P<0.05),而与临床分期及组织形态学无相关性(P>0.05)。疗效评价发现,CXCR3low组患者总反应率显著高于CXCR3high组(P=0.001),治疗有效组MCL细胞上CXCR3表达水平显著低于治疗前的表达水平(P=0.038),无效组CXCR3表达水平显著高于治疗前的表达水平(P=0.002),随访结果显示,CXCR3high组患者3年总生存时间(OS)和无进展生存时间(PFS)均显著短于CXCR3low组(均P<0.05)。结论:CXCR3在MCL中的表达水平与早期转移及预后密切相关,可作为临床疗效判断和预后评价的指标之一。Objective:To investigate the expression and clinical significance of chemokine receptor CXCR3 in mantle cell lymphoma(MCL).Methods:Flow cytometry was used to detect CXCR3 in lymph nodes and extranodal tissues in25 newly diagnosed MCL patients.The correlation of the expression of CXCR3 level with clinical features and prognostic factors was analyzed.Results:Twenty-five tumor submitted specimens all expressed CXCR3 at varied degrees.The expression levels of CXCR3 in lymph nodes(LN)and bone marrow(BM)were higher than those in peripheral blood(PB),and the expression intensity in BM positively correlated with the involved tumor numbers.The absolute values of lymphocytes and hemoglobins level in PB of CXCR3^high group were significantly lower than those in CXCR3^low group(all P<0.05).The CXCR3 expression in tumor cells significantly correlated with LDH level,β2-MG level,Ki-67 index,MIPI score and the BM involvement(all P<0.05).But,there was no correlation between the CXCR3 expression and clinical stage,histomorphology(all P>0.05).The overall response rate(ORR)in CXCR3^low group was significantly higher than that in CXCR3^high group(P=0.001).The expression level of CXCR3 in MCL cells of the effective group was significantly lower than that before treatment(P=0.038),and the CXCR3 expression in the ineffective group was significantly higher than that before treatment(P=0.002).After following up,it was found that the 3-year overall survival(OS)time and progression-free survival(PFS)time in CXCR3^high group were significantly shorter than those in CXCR3^low group(all P<0.05).Conclusion:The expression level of CXCR3 in MCL closely relates with early metastasis and prognosis.CXCR3 can be used as one of the indicators for clinical efficacy and prognosis evaluation.

关 键 词：套细胞淋巴瘤 趋化因子受体 CXCR3 表达 预后 

分 类 号：R733.1[医药卫生—肿瘤]